ICIs indications approved by FDA and EMA

Drug FDA indications EMA indications
Ipilimumab Melanoma
Non-small cell lung cancer
Renal cell carcinoma
Melanoma
Non-small cell lung cancer
Renal cell carcinoma data
Nivolumab Melanoma
Non-small cell lung cancer
Small cell lung cancer
Renal cell cancer
Classical Hodgkin’s lymphoma
Squamous cell of esophagus or head and neck
Urothelial cancer
Colorectal cancer with microsatellite instability or mismatch-repair deficiency
Hepatocellular carcinoma
Melanoma
Non-small cell lung cancer
Renal cell cancer
Classical Hodgkin’s lymphoma
Squamous cell of esophagus or head and neck
Urothelial cancer
Pembrolizumab Melanoma
Non-small cell lung cancer
Squamous cell of the head and neck
Classical Hodgkin’s lymphoma Urothelial cancer
Gastric cancer
Esophageal cancer
Cervical cancer
Renal cell carcinoma
Hepatocellular carcinoma
Colorectal cancer with microsatellite instability or mismatch-repair deficiency
Melanoma
Non-small cell lung cancer
Squamous cell of the head and neck
Classical Hodgkin’s lymphoma
Urothelial cancer
Colorectal cancer with microsatellite instability or mismatch-repair deficiency
Cemiplimab Cutaneous cell carcinoma Cutaneous cell carcinoma
Atezolizumab Urothelial carcinoma
Non-small cell lung cancer
Small-cell lung cancer
Breast cancer
Hepatocellular carcinoma
Urothelial carcinoma
Non-small cell lung cancer
Small-cell lung cancer
Breast cancer
Hepatocellular carcinoma
Avelumab Merkel cell carcinoma
Urothelial carcinoma
Renal Cell carcinoma
Merkel cell carcinoma
Urothelial carcinoma
Renal cell carcinoma
Durvalumab Urothelial carcinoma
Non-small cell lung cancer
Non-small cell lung cancer